Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Nowak

Showing results (1161-1170 of 1,216) with videos related to

Pageof 122
Sort By:
Nature Medicine|May 4, 2021
Evolution of delayed resistance to immunotherapy in a melanoma responderDavid Liu, Jia-Ren Lin, Emily J Robitschek, et al.
Nature Communications|May 21, 2016
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibitionJan A Burger, Dan A Landau, Amaro Taylor-Weiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2026
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 3, 2018
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancerMatthew B Yurgelun, Anu B Chittenden, Vicente Morales-Oyarvide, et al.
The American Journal of Gastroenterology|January 28, 2023
Molecular Characteristics of Early-Onset Colorectal Cancer According to Detailed Anatomical Locations: Comparison With Later-Onset CasesTomotaka Ugai, Koichiro Haruki, Tabitha A Harrison, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
International Journal of Cancer|April 6, 2022
Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 casesSophia Harlid, Bethany Van Guelpen, Conghui Qu, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Cancer Research|December 2, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral HeterogeneityHannah L Williams, Andressa Dias Costa, Jinming Zhang, et al.
Pageof 122

Showing results (1161-1170 of 1,216) with videos related to

Sort By:
Pageof 122
Nature Medicine|May 4, 2021
Evolution of delayed resistance to immunotherapy in a melanoma responderDavid Liu, Jia-Ren Lin, Emily J Robitschek, et al.
Nature Communications|May 21, 2016
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibitionJan A Burger, Dan A Landau, Amaro Taylor-Weiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2026
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 3, 2018
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancerMatthew B Yurgelun, Anu B Chittenden, Vicente Morales-Oyarvide, et al.
The American Journal of Gastroenterology|January 28, 2023
Molecular Characteristics of Early-Onset Colorectal Cancer According to Detailed Anatomical Locations: Comparison With Later-Onset CasesTomotaka Ugai, Koichiro Haruki, Tabitha A Harrison, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
International Journal of Cancer|April 6, 2022
Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 casesSophia Harlid, Bethany Van Guelpen, Conghui Qu, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Cancer Research|December 2, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral HeterogeneityHannah L Williams, Andressa Dias Costa, Jinming Zhang, et al.
Pageof 122